病毒样颗粒作为抗海洛因和羟考酮纳米疫苗平台的临床前表征
本研究探索病毒样颗粒(VLP)作为海洛因(M-sKLH)和羟考酮(OXY-sKLH)候选疫苗替代载体的临床前特性。两种候选疫苗分别处于后期开发或临床试验阶段(NCT04458545),其半抗原已在GMP条件下放大生产,结合物经GLP毒理学测试并由FDA在IND或pre-IND会议中审评。实验旨在检验基于VLP的疫苗能否引发有效抗体反应以减轻阿片类药物效应。
要点
- 阿片类药物使用障碍和过量仍构成公共卫生挑战,现有药物治疗可及性有限。
- 靶向阿片类药物的疫苗可诱导药物特异性多克隆抗体,在血液和器官中螯合目标药物,阻止其穿过血脑屏障。
- 本研究测试VLP作为海洛因和羟考酮候选疫苗替代载体能否引发有效抗体反应。
核心结论
- 实验旨在测试基于VLP的疫苗能否引发有效抗体反应以减轻阿片类药物效应。
研究设计与样本
- 临床前实验研究,探索VLP作为抗海洛因(M-sKLH)和羟考酮(OXY-sKLH)候选疫苗的替代载体。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Opioid use disorder (OUD) and drug-related overdoses continue to pose a major public health challenge in the United States, Canada, Europe and other countries worldwide. While effective treatments for OUD such as methadone, buprenorphine, and naltrexone, as well as overdose reversal medications such as naloxone and nalmefene, are available, access to medication assisted treatments (MATs) remains limited. This underscores the need for the development and implementation of new therapeutic strategies. As a potential strategy to address the shortcomings of current pharmacotherapies and complement their use, vaccines targeting opioids offer an additional treatment for OUD and prevention of overdose. After active immunization, vaccines trigger an immune response that generate drug-specific polyclonal antibodies that sequester the target drug in the bloodstream and organs, preventing from crossing the blood brain barrier (BBB), thereby reducing the concentration of unbound (free) drug in the brain, ultimately weakening its pharmacological and behavioral effects. Striving for more effective vaccines, a wealth of literature explored how various vaccine components can be optimized to enhance the quality and quantity of the immune response. In this landscape, drug conjugate vaccines containing virus like particles (VLP) against nicotine and opioids have been reported. Hence, this study explores use of VLPs as alternative carriers to the candidate vaccines against heroin (M-sKLH) and oxycodone (OXY-sKLH) currently in either late-stage development or in clinical trials (NCT04458545) respectively. Both the lead oxycodone (OXY) and morphine (M) haptens have been scaled up under GMP conditions, the safety of their conjugates (OXY-sKLH and M-sKLH) have been tested in GLP toxicology studies and have been reviewed by the Food and Drug Administration (FDA) in either Investigational New Drug (IND) or pre-IND meetings. The current experiments aim to test whether VLP-based vaccines can elicit an effective antibody response to mitigate opioid effects.
引用
- Tronconi D, Marecki C, Seaman RW, et al. Pre-clinical characterization of virus-like particles as a platform for nanovaccines against heroin and oxycodone. Vaccine. 2025. PMID: 40850041. doi:10.1016/j.vaccine.2025.127488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。